Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- AEO -8.8%, JRJC -5.9%, EEFT -5.4%, NTNX -3.6%, TOUR -3.6%, ANFI -2.9%, FSC -2.5%, (also approved a new common stock repurchase program)
- ADSK -1.7%, MCHP -1%, (increases guidance for non-GAAP net sales & non-GAAP EPS for 3Q17), GWRE -0.8%
Other news:
- ARWR -61.3% (will discontinue development of clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT, which utilize the DPCiv, or EX1, delivery vehicle)
- CERC -46% (announces top-line clinical results from its major depressive disorder Phase 2 clinical trial of adjunctive treatment of CERC-301; study misses primary endpoint)
- CMRE -13.7% (upsizes offering by 1 mln shares prices 12 mln shares of common stock at $6.00)
- FBP -8.9% (announces that Thomas H. Lee Partners and Oaktree commence secondary offering of 18 million shares)
- FPI -6.7% (commences 3.1 mln common stock offering)
- EVH -4.5% (Evolent Health to offer $110 mln of convertible senior notes due 2021)
- OCUL -3.4% (enters into controlled equity offering sales agreement to offer and sell shares of its common stock having an aggregate offering price of up to $40 mln)
- NLNK -2.3% (enters into Controlled Equity Offering Sales Agreement to offer and sell shares of common stock having an aggregate offering price of up to $40 mln)
- FTD -2.3% (ticking lower; CFO Becky Sheehan is leaving on Dec 31, 2016 to pursue other opportunities)
- RBS -2.2% (fails BOE stress test) .
Analyst comments:
- ABAX -0.8% (downgraded to Buy at Northcoast)
- FFIV -0.6% (downgraded to Mkt Perform from Outperform at Bernstein)